OncoMatch/Clinical Trials/NCT06624085
A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Is NCT06624085 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments for lymphoma.
Treatment: Glofitamab · Tocilizumab · Obinutuzumab · Gemcitabine · Oxaliplatin — The purpose of the study is to evaluate glofitamab + gemcitabine + oxaliplatin in participants in the United States, including under-represented racial and ethnic populations, that have relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: systemic therapy
At least one prior line of systemic therapy
Cannot have received: glofitamab or other bispecific antibodies targeting both CD20 and CD3
Prior treatment with glofitamab or other bispecific antibodies targeting both CD20 and CD3
Cannot have received: gemcitabine (gemcitabine)
Prior treatment with gemcitabine
Cannot have received: oxaliplatin (oxaliplatin)
Prior treatment with oxaliplatin
Cannot have received: monoclonal antibody
Exception: within 4 weeks prior to first study treatment
Treatment with monoclonal antibodies for the purposes of treating cancer within 4 weeks prior to first study treatment
Cannot have received: radiotherapy, chemotherapy, immunotherapy, immunosuppressive therapy, or any investigational agent
Exception: within 2 weeks prior to first study treatment
Treatment with radiotherapy, chemotherapy, immunotherapy, immunosuppressive therapy, or any investigational agent for the purposes of treating cancer within 2 weeks prior to first study treatment
Cannot have received: systemic immunosuppressive medications
Exception: within 4 weeks prior to first dose of study treatment
Prior treatment with systemic immunosuppressive medications within 4 weeks prior to first dose of study treatment
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- UC San Diego Moores Cancer Center · La Jolla, California
- Saddleback Memorial Medical Center · Laguna Hills, California
- University of California Los Angeles (UCLA) - Cancer Care - Santa Monica · Santa Monica, California
- Georgetown University · Washington D.C., District of Columbia
- AdventHealth Cancer Institute · Orlando, Florida
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify